Tarsus Pharmaceuticals, Inc.
As of Oct 22, 2026, Tarsus Pharmaceuticals is in Stage 2, the uptrend phase, now in week 5 (since Sep 21, 2026). It closed at $72.08, 20.6% below its 52-week high and above its 200-day average, which is falling.
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care
Is TARS early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
TARS among Biotechnology185th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …185 | TARS | Stage 2 · wk 5 | 56 | −3.0% |
Tarsus Pharmaceuticals: quick answers
What stage is Tarsus Pharmaceuticals in?
As of Oct 22, 2026, Tarsus Pharmaceuticals (TARS) is in Stage 2, the uptrend phase. It entered Stage 2 on Sep 21, 2026 and is in week 5. What the four stages mean
Is Tarsus Pharmaceuticals in an uptrend?
Yes. Tarsus Pharmaceuticals is in a Stage 2 uptrend. It trades 6.1% above its 200-day average, which is falling.
How far is Tarsus Pharmaceuticals from its 52-week high?
Tarsus Pharmaceuticals closed at $72.08 on Oct 22, 2026, 20.6% below its 52-week high of $90.78. Its 52-week low is $56.11.
How has Tarsus Pharmaceuticals performed over the past year?
As of Oct 22, 2026, Tarsus Pharmaceuticals is up 1.8% over the past year and down 10.8% so far in 2026.
Which sector and industry is Tarsus Pharmaceuticals in?
Tarsus Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.